U.S. allows emergency use of Eli Lilly’s COVID antibody therapy
Lilly's neutralizing antibody bamlanivimab (LY-CoV555) receives FDA emergency use authorization for the treatment of recently diagnosed COVID-19
The BLAZE-1 data show bamlanivimab, when given early in the disease course, may help patients clear the virus and reduce COVID-related hospitalizations, supporting our belief that neutralizing antibodies can be an important therapeutic option for patients fighting this virus,"
Please call if you have symptoms and concern you have covid-19 infection or already tested positive for covid-19.
Questions?
We're here to help. Send us an email or call us at 702.750.0222
REQUEST A FREE CONSULTATION